Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Solek P et al. | 2017 | intact cell/cell culture, GC-1 cells (murine spermatogonia cell line); GC-2 cells (murine spermatocyte cell line) | magnetic field, 50/60 Hz, signals/pulses | 2.5–8 mT |
Liu Y et al. | 2016 | intact cell/cell culture, GC-2 cells (murine spermatocyte-derived cell line) | magnetic field, 50/60 Hz | 1–3 mT |
Cios A et al. | 2021 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P, and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | 4.5 mT |
Cridland NA et al. | 1999 | intact cell/cell culture, HF-19 cells (human fetal lung fibroblasts) | magnetic field, 50/60 Hz | 20 µT–20 mT |
Tokalov SV et al. | 2003 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz, co-exposure | 60 µT |
Wolf FI et al. | 2005 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells); WI-38 (embryonic human lung fibroblasts); Rat-1 (rat fibroblasts) | magnetic field, 50/60 Hz | 500 µT–1 mT |
Schimmelpfeng J | 1997 | intact cell/cell culture, HL-60 (human promyelocytic leukemia cells) | magnetic field, 50/60 Hz, co-exposure | 2 mT |
Tokalov SV et al. | 2003 | intact cell/cell culture, HL-60 cells (human acute myeloid leukaemia cell line) | magnetic field, 50/60 Hz, also other exposures without EMF, co-exposure | 60 µT |
Huang CY et al. | 2014 | intact cell/cell culture, HaCaT cells (human keratinocytes) partially transfected with CHK2 siRNA | magnetic field, 50/60 Hz, shielding/field deprivation | 1.5 mT |
Harris PA et al. | 2002 | intact cell/cell culture, HeLa S3 (human cervical carcinoma cell line) | magnetic field, 50/60 Hz | 2 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.